Elastomeric Infusion Pumps Market Size & Share 2025 - 2034

Elastomeric Infusion Pumps Market Size

The global elastomeric infusion pumps market size was valued at USD 670.7 million in 2024 and is projected to exhibit 6.3% CAGR from 2025-2034. Elastomeric infusion pumps are single-use, disposable infusion devices that are used for delivering the medications such as antibiotics, chemotherapy, and pain management solutions.

Healthcare systems are focusing on home-based and outpatient care to limit hospital stays and costs. As outlined by the World Health Organization (WHO), delivery by home healthcare services significantly reduces hospitalizations, readmissions, and costs for healthcare organizations. While elastomeric infusion pumps run on no power with no complicated programming for continuous infusion delivery, many patients must use these devices and allow care to be performed in the hospital or clinic, which means they must be admitted or spend most of their day in hospital.
 

One of the best outcomes of the use of elastomeric infusion pumps is to provide patients with more comfort, less risk for infection rate due to hospital-associated care, and provide capacity to the healthcare organization. According to the Centers for Disease Control and Prevention (CDC), an estimated 1 in 31 hospital patients has at least one healthcare-associated infection (HAI) on any given day in the U.S. Therefore, the need for home-based clinical care, is driving the demand for elastomeric infusion pumps.
 

Home-based treatment for chronic conditions such as cancer, thalassemia, and other autoimmune disorders gained momentum due to COVID-19, which raised the demand for optimal therapy delivery methods including the use of elastomeric infusion pumps. With increasing prevalence of chronic diseases and growing focus towards value-based care, the demand for homecare treatment devices has continued post-pandemic. WHO states that chronic conditions are responsible for 71% of deaths in the world annually with cancer resulting in nearly 10 million deaths worldwide in 2020.
 

Home healthcare service providers are extensively deploying elastomeric infusion pumps for chemotherapy as well as for immunoglobulin and iron chelation therapy. This has allowed patients to receive consistent and ongoing drug administration without requiring hospitalization. As per the National Institutes of Health (NIH), administering chemotherapy at-home as opposed to day-care in hospital can result in significant resource optimization for hospitals and financial relief for patient. As a result, the demand for home-care is increasing, further fuelling the demand for elastomeric infusion pumps.
 

Elastomeric Infusion Pumps Market Trends

• The use of elastomeric infusion pumps in oncology care is slowly being adopted for outpatient chemotherapy. These pumps allow patients to receive constant drug delivery while performing their regular activities.
• This evolution in outpatient chemotherapy is being fuelled by growing focus towards reducing hospital length of stays for patients, reducing treatment costs, and improving quality of life for patients. As the rates of cancer increase world-wide in older populations, the adoption of outpatient chemotherapy is further expected to grow exponentially.
   
• Further, adoption of home healthcare services is increasing in emerging countries that are facing healthcare workforce shortages, which is further bolstering the demand for infusion options, as patients self-administer medications themselves. Elastomeric pumps are finding extensive use across home -based care as they offer a low-maintenance, non-electronic, portable option, particularly for antibiotics, antivirals, and pain management. Government across emerging countries are focusing on decentralizing healthcare to reduce strain on the healthcare system.
   
• Manufacturers are focusing on developing elastomeric devices using next-generation elastomeric material system to increase flow rate precision, temperature change resistance, and device wear. These advancements are overcoming challenges associated with elastomeric technology and increasing the reliability and acceptability of elastomeric pumps for a broader array of clinical uses.
   

Elastomeric Infusion Pumps Market Analysis

Based on product type, the market is segmented into continuous rate elastomeric pumps and variable rate elastomeric pumps. The continuous rate elastomeric pumps segment dominated the market with the largest revenue share of 69.2% in 2024.
 

• Continuous rate elastomeric pumps are preferred for delivering the same medication over time as continuous rate is essential, especially in controlling chronic conditions, such as cancer, pain, infections, and autoimmune diseases.
   
• In addition, keeping an infusion rate constant provides therapeutic effectiveness, lowers the chance of under or overdosing, and makes continuous elastomeric pumps appropriate for long-term therapies in both inpatient and outpatient settings.
   
• In addition, with growing focus towards value-based care, the demand for reliable infusion pump has become inadvertent. Continuous rate elastomeric pumps are non-battery dependent with no programming requirements; thus, they are simple to use for both the patient and caregiver promoting improved independence and adherence in home infusion settings.
   
• Owing to the above advantages, the reliability of continuous rate elastomeric pumps is contributing to their increase usage in ambulatory care, resulting in revenue growth in the segment.
   

Based on application, the elastomeric infusion pumps market is segmented into pain management, chemotherapy, antibiotic delivery, antiviral treatment, and other applications. The pain management segment dominated the market with the largest revenue of USD 249.8 million in 2024 and is also expected to grow at a significant CAGR over the forecast period.
 

• With more surgeries being performed worldwide, there is a focus on post-operative pain management that is effective in supporting patient recovery and reducing length of stay in hospital.  Elastomeric pumps are used in practice to deliver continuous doses of analgesics using either local anesthetics or opioids, thus offering consistent pain relief without the complexity of equipment or active monitoring.
   
• Their portability and simplicity allow them to be used where ambulatory surgery occurs and as part of enhanced recovery after surgery (ERAS) protocols.
   
• The use of regional anesthesia techniques and continuous peripheral nerve blocks in conjunction with elastomeric pumps for post-surgical pain relief continues to be adopted, allowing patients to receive continuous, uninterrupted analgesia at home post-operatively through a perineural catheter.
   
• As a result of these benefits, there is an increase in demand for elastomeric pump solutions across multiple specialties, including orthopedic, thoracic, abdominal surgery, and anesthetic practices, which is driving the revenue growth in the segment.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the elastomeric infusion pumps market is segmented into hospitals, ambulatory surgical centers, home care settings, and other end users. The hospitals segment dominated the market with the largest revenue share of 47.8% in 2024.
 

• Hospitals are increasingly exploring the use of elastomeric pumps for post-operative pain management and medications such as analgesics or antibiotics in a consistent and effective manner. Elastomeric pumps offers a continuous infusion, and eliminates reliance on electronic controls, which helps hospitals to streamline workflows within busy surgical wards and surgical recovery units.
   
• Eliminating the need for a frequent nurse intervention improves patient comfort as well as support the hospital's goal of improving overall care and improving efficiencies on resources.
   
• Infection prevention has become a top priority in the hospital environment. As per World Health Organization, According to a study by Balasubramanian et al., in 2023, around 136 million cases of antibiotic-resistant infections linked to healthcare happen globally each year. Owing to their single-use and disposable characteristics, elastomeric pumps present lower rates of exposure to cross contamination, unlike reusable electronic pumps. As a result, their use is increasing across these acute care inpatient settings to avoid healthcare associated infections.
   
• Further, their sterile, self-contained systems make them ideally suited to hospital protocols, especially in oncology, critical care or surgical units where asepsis is needed. This trend is likely accelerating as hospitals are favoring the single-use, disposable infusion solutions.

The North America elastomeric infusion pumps market was valued at USD 299.8 million in 2024 and is expected to grow at a CAGR of 6.2% over the forecast period. The market is driven by the increasing aging population and growing focus on value-based care across the region.
 

The U.S. market is projected to grow significantly from USD 270.6 million in 2024 to USD 504.7 million by 2034.
 

• The U.S. healthcare system is increasingly shifting procedures to outpatient environments to decrease expenses and improve patient services. Elastomeric infusion pumps are widely used in ambulatory surgical centers and home care for post-operative pain control, antibiotic therapy, and chemotherapy.
   
• Their ease of use and portability support the movement of same-day discharges and home recovery in the U.S.
   
• Favorable reimbursement policies for infusion therapy, in particular Medicare Part B and DME (durable medical equipment) coverage, favor elastomeric pumps in outpatient and home environments.
   
• U.S. insurers often view elastomeric pumps as efficient and reasonable upcoming infusion options to help reduce the inpatient length of stay, assisting the buy-in of elastomeric pumps by hospitals and home infusion providers who desire to transition and align with value-based care models.
   

Europe elastomeric infusion pumps market was valued at USD 169 million in 2024 and is expected to grow at a CAGR of 6% over the forecast period.
 

• Numerous European countries, particularly in Western Europe, are embracing hospital-at-home programs as a way to reduce health care dependence on inpatient care and overall improve health care efficiencies.
   
• Elastomeric infusion pumps are essential components of these models, as they deliver medication continuously and safely outside of a hospital setting without the need for electronic devices. This has provided opportunities for patient comfort and also complements national healthcare cost containment measures without compromising care.
   
• There have been strong pushes towards antimicrobial stewardship in Europe. The European Centre for Disease Prevention and Control and European Food Safety Authority has issued guidelines regarding the optimal dose and duration of antibiotics in humans and animals.
   
• More elastomeric pumps are utilized in the administrative delivery of outpatient parenteral antibiotic therapy (OPAT), especially in the UK, Germany, and Netherlands. The delivery of intravenous antibiotics via elastomeric pumps allows for continuous infusion of medication, keep therapeutic drug levels achieved in the hospital, and reduce hospital days while aiding infection control targets as identified by EU health bodies.
   

The elastomeric infusion pumps market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The UK has one of the most developed OPAT frameworks in Europe, with national NHS guidance. The use of elastomeric pumps is fundamental to OPAT services, as they allow patients to receive continuous intravenous antibiotics either at home or in community clinics.
   
• The equipment enables high-quality care that is safe, convenient, portable and reliable, and directly aligns with the NHS approach to minimize inpatient stays, reduce hospital admissions, and deliver more effective management of infection in the outpatient space.
   
• The NHS is keen to advocate value-based procurement with a focus on technologies that provide cost-savings even whilst maintaining or improving on clinical outcomes.
   
• In this context, elastomeric pumps are a cost-effective solution, disposable, manual and non-electronic, which brings significant benefit compared with programmable infusion devices, and with much less financial investment in maintenance and staff training. As a result, with NHS facing budgetary deficits, elastomeric pumps have become a necessary alternative in medication delivery in the UK.
   

The Asia Pacific elastomeric infusion pumps market is expected to grow at the fastest CAGR of 7% over the forecast period.
 

• Numerous countries in the APAC region, including India, Indonesia, and the Philippines, are seeking to gain healthcare access in rural and semi-urban settings where electricity or other electronic device infrastructure is limited. This has surged the use of elastomeric pumps, that can operate without electricity and without requiring any complex training for their use.
   
• Elastomeric pumps' portability, simplicity and low-cost make them fit for purpose in resource-limited environments across emerging countries in Asia Pacific region, and are providing impetus for adoption across public health agencies or outreach programs in this region.
   
• While countries such as China, Japan, and South Korea, have seen a significant shift to greater ambulatory surgical procedures facilitated by urbanization and changing models of health care delivery, elastomeric pumps are increasingly used in these ambulatory surgical facilities as a part of pain management for post-operative patients, and for the delivery of antibiotics or chemotherapy drugs.
   
• The use of elastomeric pumps in APAC outpatient facilities enables ease of use and proven reliability that allows for greater patient turnover, which is an essential operational requirement across high volume APAC outpatient facilities.
   

Japan elastomeric infusion pumps market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Japan has one of the oldest populations in the world, which has resulted into high prevalence of chronic diseases like cancer, cardiovascular illnesses, and infections requiring long-term intravenous therapy. For instance, as per WHO 2023 stats, ischemic heart diseases and stroke were the leading cause of death in Japan contributing to 148.5 deaths and 103.3 deaths per 100,000 population respectively.
   
• To minimize health care burden and optimize the patient experience, the Japanese health care system is supporting more home treatment options, which is driving the demand for elastomeric pumps in Japan.
   
• Japan's healthcare system prioritizes optimizing cancer care delivery through outpatient chemotherapy and day-care centers. The use of elastomeric pumps for continuous infusion of cytotoxic chemotherapy agents such as 5-FU, which is often administered in the outpatient chemotherapy units, is increasing.
   
• These models are helping to reduce strain on inpatient resources and enhance patient's quality of life in Japan. Accordingly, elastomeric pumps have become an integral part of modern-day oncology protocols in Japan, positively impacting patient care and experience.
   

Brazil elastomeric infusion pumps market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Brazil has a dual healthcare system which focuses on easing public healthcare access through Brazil's Unified Health System (SUS). The growing access towards free/reimbursed healthcare treatments through SUS helps to ease an access towards infusion therapy across inpatient and outpatient settings, further driving the demand for elastomeric pumps in Brazil.
   
• Elastomeric pumps are becoming increasingly popular for both sectors of the dual system due to their affordability and advantageous for-home use as a decentralized healthcare solution. Elastomeric pumps do not have many obstacles for administration and portable use helps to broaden the scope of treatment suitability, especially in impoverished or rural communities.
   
• With rising cancer rates and chronic infections including osteomyelitis, Brazil is experiencing an increasing demand for efficient, cost-conscious continuous infusion therapies. According to Government of Brazil, 704,000 new cases of cancer were reported for 2023 in the country.
   

The Saudi Arabia elastomeric infusion pumps market in Middle East and Africa is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia Vision 2030 involves a significant overhaul of its healthcare system regarding new investment, particularly for home care, day surgery centers, and outpatient services.
   
• Elastomeric infusion pumps have become a part of modernization plan, supplying safe drug delivery without the need for cumbersome infrastructure. The devices are designed to be portable and easy to use, allowing for care decentralization and reduced hospital dependence, and align with the Saudi Arabia’s transformation strategy for healthcare.
   
• Further, increased cancer rates in Saudi Arabia also increasing the use of outpatient chemotherapy and palliative care services. According to the Global Cancer Observatory, about 28,113 new cases of cancer were reported in the country in 2022. As a result, the use of elastomeric pumps for extended delivery of 5-FU and other chemotherapy agents, in single or multiple agent formats, is finding wider acceptance for ambulatory treatment of cancer.
   

Elastomeric Infusion Pumps Market Share

The market has a dynamic mix of international and domestic players providing innovative solutions to meet the growing demand for advanced treatments for the growing patient population. Companies such as B. Braun, Baxter, Fresenius Kabi, Smiths Medical, and Avanos Medical are some of the dominant competitors in the market accounting for a combined market share of approximately 75%.
 

Competition in this area arises from continuous technological developments and the ability to offer customized solutions. In developing nations, due to the priority given to cost, multinational companies are squeezed to offer elastomeric infusion pumps that are both affordable and of quality. Domestic manufacturers take advantage of this demand by providing cost effective alternatives, which make multinationals alter their price strategy while maintaining the safety, ruggedness, and regulatory acceptability of the products.
 

Elastomeric Infusion Pumps Market Companies

Some of the eminent market participants operating in the elastomeric infusion pumps industry include:

• ACE Medical
• Ambu
• Avanos
• B. Braun
• Baxter
• Fresenius Kabi
• Halyard
• ICU Medical
• JMS
• KB Medical
• Leventon
• Nipro
• Smiths Medical
• Terumo
• Woo Young Medical
   
• B. Braun leads the competition with its clinically validated, German-engineered infusion systems that safety, accuracy, and ease of use are at the forefront. Their elastomeric pumps have become a staple in hospitals for several reasons, including predictable flow rates, low occlusion risk, and adherence to strict EU/US regulatory standards. In part, due to B. Braun’s clinical support and many education programs, healthcare providers looking for reliability in critical care can count on elastomeric pumps, including customizable options for chemotherapy and antibiotics.
   
• Baxter offers a noteworthy offering of patient-centered elastomeric pumps designed for home infusion therapy. Their devices have a lightweight, portable design, and focus on intuitive utilization that limits nursing burden and additional dependency. Baxter has potential with smart pump connectivity and is uniquely innovating as a digital health provider.
   
• Fresenius Kabi offers high quality and cost-efficient elastomeric pumps.  They are well known across cost-sensitive markets. Elastomeric pumps offered by the company are very durable, have an extremely long shelf life, and can be used with multiple therapies. The company is also committed to sustainability.
   

Elastomeric Infusion Pumps

• In April 2024, Baxter International, one of the leading company in infusion therapies and technologies, announced the U.S. FDA approval and 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software. By offering the Novum IQ LVP in the U.S., Baxter is showcasing its dedication to ongoing innovation in the field of infusion therapy.
   
• In January 2023, B. Braun announced its manufacturing capacity expansion through 310,000 square foot facility with an investment of about USD 200 million, in Allentown, Pennsylvania, U.S. This initiative is set to transform the manufacturing of medical devices, particularly life-saving infusion therapy devices that will help millions of patients across the U.S.
   

The elastomeric infusion pumps market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

By Product

• Continuous rate elastomeric pumps
• Variable rate elastomeric pumps

By Application

• Pain management
• Chemotherapy
• Antibiotic delivery
• Antiviral treatment
• Other applications

By End Use

• Hospitals
• Ambulatory surgical centers
• Home care settings
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific 
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE